Health care providers play a dual role in ensuring that all people, including minority groups, benefit equally from pharmacogenomics and precision medicine. First, providers help translate and incorporate findings from pharmacogenomics research studies into their clinical practice, ensuring that patients receive the medications that will be most effective for them. Second, providers also educate patients about pharmacogenomics and the importance of participating in related research studies.
See below for frequently asked questions about ACCOuNT from health care providers. If you have additional questions about ACCOuNT, please submit them here. We will post answers to some of these questions on this page.
You may also contact us directly if you would like to speak with the ACCOuNT researchers.
What diseases is ACCOuNT studying?
Currently, ACCOuNT is focusing on thrombotic diseases and is collecting data from patients starting therapy with the following medications: Clopidogrel, warfarin, and new oral anticoagulants.
Over time, we hope to study many diseases. We are building a large data warehouse to store data and share information with a broad array of clinicians and other investigators conducting research in pharmacogenomics.
What has pharmacogenomics research already taught us about blood clotting among African American populations?
Several ACCOuNT investigators have conducted work in this area previously. One prior study
found that some genetic risk factors for Venous Thromboembolism (VTE) are more common among populations of African descent. These genetic factors may explain why African Americans have a higher incidence of (VTE) than other populations. Another previous study
found genetic factors that affect responses to warfarin in African American populations.
What have we learned from ACCOuNT so far? Where can I read about the results?
ACCOuNT is at the beginning stages of a multi-year study. When findings become available, we will post them on this website.
How do I know if a pharmacogenomics research study is inclusive of a particular patient population or representative of the population as a whole?
To date, very few pharmacogenomic research studies have examined how genetic variations among populations of African ancestry impact drug response. When reading a relevant peer-reviewed journal article, you should review the methods section for descriptive statistics about the demographics, including race and ethnicity, of the sample.
What resources are there to help me use pharmacogenomics and precision medicine research in my clinical practice?
to see a list of existing tools and resources for clinicians.
What should I teach my patients about pharmacogenomics research?
As a clinician, you can help teach patients that some genetic variations, which might be more common in some racial or ethnic groups than others, may impact the clinical effect of certain medications. You can also explain that more research needs to be done in this area to ensure that all people, including minority groups, benefit equally from pharmacogenomics. Clinicians may refer patients to our Resources
page for more general information about pharmacogenomics and precision medicine.
I’m an allied health professional (pharmacist, nurse, etc.). How can I help ensure that precision medicine benefits all people equally?
You have an important role in educating patients about pharmacogenomics and referring patients to participate in research studies. It is important that you remain informed on the newest findings in pharmacogenomics so that you can provide patients with the most up-to-date information.